Compare Abbott Laboratories (ABT) vs MPLX LP (MPLX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs MPLX LP — how do they compare? Abbott Laboratories trades at $95.64 (market cap $166.94B), while MPLX LP trades at $56.91 (market cap $58.36B). The key difference: Abbott Laboratories is far larger — about 2.9× MPLX LP's market cap, and MPLX LP pays the higher dividend (7.49%). Which is the better fit depends on your goals.
| ABT | MPLX | |
|---|---|---|
Market Cap | $166.94B | $58.36B |
Sector | Health | Technology |
52-Week High | $136.62 | $59.17 |
52-Week Low | $82.57 | $47.80 |
Enterprise Value | $193.69B | $82.99B |
Dividend Yield | 2.63% | 7.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
MPLX trades at $56.97, down 0.33% on the day, with a bullish technical signal supported by moving averages and key indicators like ADX. Financially, the company reported strong 2025 results with $11.47B revenue and $4.91B net income, though Q1 2026 EPS missed expectations. Analyst consensus is strongly positive with a $60.60 price target, and the recent $1.08 dividend underscores its income appeal.
The outlook for MPLX remains favorable, driven by its high-yield dividend, stable cash flows from fee-based contracts, and strategic focus on natural gas and NGL services. Key risks include exposure to energy commodity volatility and high debt levels. Upside potential hinges on execution of growth projects and sustained distribution growth amid a supportive midstream environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About MPLX LP
MPLX LP is a Master Limited Partnership (MLP) formed by Marathon Petroleum Corporation (MPC). It is a diversified, growth-oriented company primarily engaged in the gathering, processing, and transportation of natural gas and natural gas liquids (NGLs), as well as the transportation, storage, and distribution of crude oil and refined petroleum products. MPLX owns and operates a network of midstream energy infrastructure assets, providing essential services to the energy industry across the United States.
Read more on MPLX →
